The dimethylglycine dehydrogenase (DMGDH) antibody is a crucial tool for studying the enzyme DMGDH, which plays a pivotal role in mitochondrial one-carbon metabolism. DMGDH catalyzes the oxidative demethylation of dimethylglycine to sarcosine, generating NADH and 5.10-methylene-tetrahydrofolate—a key intermediate in folate-mediated processes. This enzyme is primarily expressed in the liver and kidneys, linking choline catabolism to the mitochondrial folate cycle, thereby influencing nucleotide synthesis, methylation reactions, and redox homeostasis. DMGDH dysfunction has been implicated in dimethylglycinuria, a rare metabolic disorder characterized by elevated dimethylglycine levels, though its clinical significance remains under investigation. Recent studies also suggest potential associations between DMGDH activity and age-related diseases, cancer metabolism, and neurological disorders, spurring interest in its regulatory mechanisms. The DMGDH antibody enables detection and quantification of DMGDH protein in various experimental models, facilitating research into its tissue-specific expression, post-translational modifications, and interactions within metabolic networks. It is widely employed in techniques like Western blotting, immunohistochemistry, and immunofluorescence to explore DMGDH's roles in health and disease. As mitochondrial energy metabolism gains attention in precision medicine, this antibody serves as a vital reagent for deciphering DMGDH's contributions to cellular physiology and pathology.